4:51 pm Novartis AG confirms FDA approval for Zykadia, first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
View todays social media effects on NVS
View the latest stocks trending across Twitter. Click to view dashboard
See who Novartis is hiring next, click here to view
